Open Orphan Plc (GB:HVO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Open Orphan Plc, a leading contract research organization, has announced positive results from a Phase 2a RSV human challenge trial for Enanta Pharmaceuticals’ antiviral candidate EDP-323. The trial demonstrated the candidate’s safety, tolerability, and significant antiviral effect in reducing viral load and clinical symptoms in healthy adults. hVIVO’s expertise in human challenge trials continues to support the accelerated development of respiratory disease treatments.
For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.